Mr. Julius Kalcevich reports

CYTOPHAGE ANNOUNCES CLOSING DATE OF ITS NON-BROKERED PRIVATE PLACEMENT

Cytophage Technologies Ltd. will proceed to close its previously announced non-brokered unit private placement. The full details of the offering were announced in a press release dated Oct. 17, 2025.

The company has received orders and indications for approximately six million units, representing approximately $1.2-million of proceeds. The company anticipates that it will close the offering on Nov. 10, 2025, with a secondary tranche as necessary on Nov. 17, 2025.

As stated in its earlier press release, the company may increase the size of the offering by up to $600,000 to accommodate additional demand from investors who continue to evaluate the company.

About Cytophage Technologies Ltd.

Cytophage Technologies is a pioneering biotechnology company dedicated to bacteriophage research, product development and commercialization.

Bacteriophages are viruses that only infect and kill bacteria. These natural killers of bacteria can overcome cellular or organism-level defences. They are nature's version of antibiotics.

Cytophage is improving bacteria's natural predators with environmental as well as genetic modifications to bring safe and toxin-free killer solutions to large addressable markets with an initial focus on animal health which offers a fast-track to near-term revenue. As a leading bacteriophage manufacturer in Canada and powered by a large library of phage strains, Cytophage is committed to addressing the global challenge of antibiotic resistance (AMR). The WHO predicts that AMR will be the leading cause of human mortality by 2050. Many countries have already banned or limited preventative antibiotic use in animal production including 27 European Union countries, United States, Canada, Brazil, Bangladesh, India and Mexico. In addition to that, consumers all over the world are demanding organic and antibiotic-free products.

Cytophage is using a derisked and patented technology to advance innovative and cost-competitive products that harness the power of bacteriophages to combat bacterial infections affecting human health, animal health and food security.

We seek Safe Harbor.